Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Autor:	Chan, Arlene, Moy, Beverly, Mansi, Janine, Ejlertsen, Bent, Holmes, Frankie Ann, Chia, Stephen, Iwata, Hiroji, Gnant, Michael, Loibl, Sibylle, Barrios, Carlos H., Somali, Isil, Smichkoska, Snezhana, Martinez, Noelia, Alonso, Mirta Garcia, Link, John S., Mayer, Ingrid A., Cold, Søren, Murillo, Serafin Morales, Senecal, Francis, Inoue, Kenichi, Ruiz-Borrego, Manuel, Hui, Rina, Denduluri, Neelima, Patt, Debra, Rugo, Hope S., Johnston, Stephen R.D., Bryce, Richard, Zhang, Bo, Xu, Feng, Wong, Alvin, Martin, Miguel
Zdroj:	In Clinical Breast Cancer February 2021 21(1):80-91
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect